Skip to content

Helping patients reclaim a life of possibility

Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE

What we do

  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
      • AL amyloidosis vs myeloma
      • Living with AL amyloidosis
      • Diagnosis, treatment and monitoring of AL amyloidosis
      • CAR T-cell therapy side effects
      • Minimal Residual Disease (MRD)
      • Chimeric Antigen Receptor T cell (CAR-T) therapy
      • SARS-CoV-2 (COVID-19) Vaccination and Treatment
      • European Union (EU) Funded Projects
      • Health Technology Assessment (HTA)
      • H2020 MMPredict
    • Toolkits
    • Factsheets
      • Melphalan flufenamide
      • Teclistamab
      • Ciltacabtagene autoleucel
      • Idecabtagene vicleucel
      • Isatuximab
      • Selinexor
      • Thalidomide
      • Lenalidomide
      • Pomalidomide
      • Bortezomib
      • Daratumumab
      • Panobinostat
      • Elotuzumab
      • Ixazomib
      • Carfilzomib
      • Amyloidosis
      • Belantamab mafodotin
      • Stem cell transplant
    • Patient guides

Subscribe to
our newsletter!

Subscribe here

Webinars

This webinar, organised by the MPE European Young Myeloma Patient Group (EYMPG), was given by Dr. Charlotte Pawlyn is a Clinician Scientist and Team Leader at the Institute of Cancer Research and an Honorary Consultant Haematologist at The Royal Marsden Hospital in London, UK.
Prev 1 of 5 Next
  • Webinar EYMPG | Side effects and management of myeloma treatment

    Webinar EYMPG | Side effects and management of myeloma treatment

  • ASCERTAIN webinar | How are costs and medicine effectiveness part of decision-making in access?

    ASCERTAIN webinar | How are costs and medicine effectiveness part of decision-making in access?

  • MPE webinar Myeloma and infection

    MPE webinar Myeloma and infection

  • European Young Myeloma Patients Group | Latest developments in treatments for young myeloma patients

    European Young Myeloma Patients Group | Latest developments in treatments for young myeloma patients

  • MPE Webinar | EHA 2025 highlights

    MPE Webinar | EHA 2025 highlights

  • MPE webinar | Living well with AL amyloidosis

    MPE webinar | Living well with AL amyloidosis

  • Webinar | ‘How do different countries make decisions on reimbursing new medicines?’

    Webinar | ‘How do different countries make decisions on reimbursing new medicines?’

  • Webinar EYMPG | Myeloma and physical fitness

    Webinar EYMPG | Myeloma and physical fitness

  • MPE webinar: ASH 2024 myeloma and AL amyloidosis highlights

    MPE webinar: ASH 2024 myeloma and AL amyloidosis highlights

  • Webinar EYMPG | Importance of good nutrition and healthy diet for young myeloma patients

    Webinar EYMPG | Importance of good nutrition and healthy diet for young myeloma patients

  • MPE webinar | Disease and treatment specificities for young myeloma patients

    MPE webinar | Disease and treatment specificities for young myeloma patients

  • MPE Webinar | EHA 2024 myeloma highlights

    MPE Webinar | EHA 2024 myeloma highlights

Prev 1 of 5 Next
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2025
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month 2025
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.